Does Rallies show 13F holders for XBI?

Yes. Rallies tracks hedge fund and 13F ownership data for XBI, including fund names, share counts, latest tracked quarter, and position changes when available.

Is XBI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for XBI. It does not provide personalized investment advice.

XBI (Biotech) Stock Analysis - Hedge Fund Holdings

Biotech (XBI) is a publicly traded the market company. As of May 20, 2026, XBI trades at $131.56 with a market cap of $0 and a P/E ratio of 0.00. XBI moved +3.92% today. Year to date, XBI is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces XBI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns XBI stock?

Hedge funds tracked by Rallies that own XBI include Bluecrest Capital, Orbimed Advisors, Rokos Capital, and Chilton Investment. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Biotech.

XBI Key Metrics

Key financial metrics for XBI
Metric	Value
Price	$131.56
Market Cap	$0
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$0.00
52-Week Low	$0.00
Volume	10.38M
Avg Volume	0
Revenue (TTM)	$0
Net Income	$0
Gross Margin	0.00%

Top Hedge Funds Holding XBI

Bluecrest Capital holds 1.53M shares of XBI, changed +0.00% as of Dec 31, 2024.
Orbimed Advisors holds 372.00K shares of XBI, changed +0.00% as of Dec 31, 2024.
Rokos Capital holds 81.96K shares of XBI, changed +0.00% as of Dec 31, 2025.
Chilton Investment holds 2.80K shares of XBI, changed +0.00% as of Dec 31, 2024.

Latest XBI News

XBI flat as biotech M&A tailwinds meet mixed earnings and rate sensitivity — May 7, 2026
XBI flat as biotech catalysts and rate sensitivity offset broader risk appetite — May 6, 2026
XBI flat as biotech sentiment stabilizes, with rates and catalysts in focus — May 5, 2026
XBI treads water as biotech catalysts compete with rate-driven risk sentiment — May 4, 2026
XBI trades flat as May FDA catalyst slate meets steady-but-high U.S. yields — May 1, 2026

XBI Analyst Consensus

XBI analyst coverage data. Average price target: $0.00.

Common questions about XBI

Who owns XBI stock?: Hedge funds tracked by Rallies that own XBI include Bluecrest Capital, Orbimed Advisors, Rokos Capital, and Chilton Investment. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Biotech.
Does Rallies show 13F holders for XBI?: Yes. Rallies tracks hedge fund and 13F ownership data for XBI, including fund names, share counts, latest tracked quarter, and position changes when available.
Is XBI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for XBI. It does not provide personalized investment advice.